IL-15 in CAR engineering: striking an efficacy–safety balance
Interleukin (IL)-15 engineering in chimeric antigen receptor (CAR)-cell therapy has demonstrated promising antitumor efficacy against both hematological malignancies and solid tumors in recent clinical trials. However, increased cytokine release syndrome (CRS) toxicity is primarily observed in conventional CAR-T cells, underscoring the need to balance safety and efficacy in IL-15-enhanced CAR therapy for clinical application.
Authors
- Yan-Ruide Li
- Yichen Zhu (ORCID: https://orcid.org/0009-0008-9188-066X)
- Lili Yang
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- Trends in Molecular Medicine
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1016/j.molmed.2025.05.014
- Citations
- 18
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 18.82